Oral Session 3-10A MM: Clinical trials

[OS3-10A-6] KEYNOTE185: Randomized phase 3 study of Len/dex±pembrolizumab in untreated MM (including JPN subset)

Hiroshi Kosugi¹, Naoki Takezako², Morio Matsumoto³, Shinsuke Iida⁴, Takayuki Ishikawa⁵, Yukio Kondo⁶, Kiyoshi Ando⁷, Takaaki Cho⁸, Hirokazu Miki⁹, Itaru Matsumura¹⁰, Kazutaka Sunami¹¹, Takanori Teshima¹², Hiromi Iwasaki¹³, Yasushi Onishi¹⁴, Masahiro Kizaki¹⁵, Koji Izutsu¹⁶, Dai Maruyama¹⁶, Kensei Tobinai¹⁶, Kenshi Suzuki¹⁶ (1.Ogaki Municipal Hospital, Gifu, Japan, 2.NHO Disaster Medical Center, Tokyo, Japan, 3.NHO Shibukawa Medical Center, Gunma, Japan, 4.Nagoya City University Hospital, Aichi, Japan, 5.Kobe City Medical Center General Hospital, Hyogo, Japan, 6.Kanazawa University Hospital, Kanazawa, Japan, 7.Tokai University Hospital, Kanagawa, Japan, 8.Niigata Cancer Center Hospital, Niigata, Japan, 9.Tokushima University Hospital, Tokushima, Japan, 10.Kindai University Hospital, Osaka, Japan, 11.NHO Okayama Medical Center, 12.Hokkaido University Hospital, Hokkaido, Japan, 13.NHO Kyushu Medical Center, 14.Tohoku University Hospital, Miyagi, Japan, 15.Saitama Medical Center, Saitama Medical University, Saitama, Japan, 16.National Cancer Center Hospital, Tokyo, Japan, 17.Japanese Red Cross Medical Center, Tokyo, Japan)